Cardoso F - Search Results

1

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. de Azambuja E, et al. Among authors: cardoso f. ESMO Open. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793. ESMO Open. 2020. PMID: 32439716 Free PMC article. Review.

2

Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ. Colozza M, et al. Among authors: cardoso f. Oncologist. 2006 Feb;11(2):111-25. doi: 10.1634/theoncologist.11-2-111. Oncologist. 2006. PMID: 16476832 Free article. Review.

3

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Colozza M, et al. Among authors: cardoso f. Oncologist. 2007 Mar;12(3):253-70. doi: 10.1634/theoncologist.12-3-253. Oncologist. 2007. PMID: 17405890 Free article. Review.

4

Molecular targeted therapies in breast cancer: where are we now?

Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M. Widakowich C, et al. Among authors: cardoso f. Int J Biochem Cell Biol. 2007;39(7-8):1375-87. doi: 10.1016/j.biocel.2007.04.015. Epub 2007 May 4. Int J Biochem Cell Biol. 2007. PMID: 17543572 Review.

5

Current perspectives of epothilones in breast cancer.

Cardoso F, de Azambuja E, Lago LD. Cardoso F, et al. Eur J Cancer. 2008 Feb;44(3):341-52. doi: 10.1016/j.ejca.2007.11.019. Eur J Cancer. 2008. PMID: 18178426 Review.

6

[The new generation of breast cancer clinical trials: the right drug for the right target].

de Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M. de Azambuja E, et al. Among authors: cardoso f. Bull Cancer. 2008 Mar;95(3):352-7. doi: 10.1684/bdc.2008.0587. Bull Cancer. 2008. PMID: 18390416 Review. French.

7

Facts and controversies in the use of trastuzumab in the adjuvant setting.

Dinh P, de Azambuja E, Cardoso F, Piccart-Gebhart MJ. Dinh P, et al. Among authors: cardoso f. Nat Clin Pract Oncol. 2008 Nov;5(11):645-54. doi: 10.1038/ncponc1219. Epub 2008 Sep 9. Nat Clin Pract Oncol. 2008. PMID: 18779850 Review.

8

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Snoj N, Bedard PL, de Azambuja E, Cardoso F, Piccart M. Snoj N, et al. Among authors: cardoso f. Breast Cancer Res. 2009;11(1):201. doi: 10.1186/bcr2209. Epub 2009 Jan 16. Breast Cancer Res. 2009. PMID: 19216727 Free PMC article. Review.

9

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

Bedard PL, de Azambuja E, Cardoso F. Bedard PL, et al. Among authors: cardoso f. Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. doi: 10.2174/156800909787581024. Curr Cancer Drug Targets. 2009. PMID: 19275756 Review.

10

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F; ESO-MBC Task Force. Pagani O, et al. Among authors: cardoso f. J Natl Cancer Inst. 2010 Apr 7;102(7):456-63. doi: 10.1093/jnci/djq029. Epub 2010 Mar 10. J Natl Cancer Inst. 2010. PMID: 20220104 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,469 results

Search Page

Filters